What Armata Pharmaceuticals, Inc. does.

We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.

We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile . We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or “superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity and potency, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.

Revenue and profit, by fiscal year.

More on ARMP.

• Armata Pharmaceuticals, Inc. summary
• Armata Pharmaceuticals, Inc. financial statements
• Armata Pharmaceuticals, Inc. key metrics
• Armata Pharmaceuticals, Inc. health scores and style box
• Armata Pharmaceuticals, Inc. earnings
• Armata Pharmaceuticals, Inc. dividends
• Armata Pharmaceuticals, Inc. valuation
• Armata Pharmaceuticals, Inc. ownership and insiders
• Armata Pharmaceuticals, Inc. peers

Figures from Armata Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.